Mucosal vaccines

Patent metadata

Field	Value
Publication number	US-9540420-B2
Application number	US-201113582160-A
Country	US
Kind code	B2
Filing date	Mar 1, 2011
Priority date	Mar 2, 2010
Publication date	Jan 10, 2017
Grant date	Jan 10, 2017

Abstract

A mucosal vaccine producing an antigen-specific mucosal IgA and a blood IgG in the levels capable of exerting an effective immune induction and an infection-preventing effect, which comprises:
(a) an AD vehicle consisting of a synthetic peptide and a lipid(s), wherein the synthetic peptide consisting of the amino acid sequence KnLm (wherein n is 4 to 8 and m is 11 to 20); (b) a carboxylvinyl polymer; and, (c) an antigenic protein, in an amount incapable of producing a sufficient mucosal IgA and blood IgG for exerting an effective immune induction and an infection-preventing effect when used by itself.

The mucosal vaccine of the invention has an antibody producing ability which is more potent than those of mucosal vaccines of the prior art, and as a result it can exert an excellent effect even with an extremely small amount of an antigen.

First claim

The invention claimed is:

1. A mucosal vaccine producing an antigen-specific mucosal IgA and blood IgG in the levels capable of exerting an effective immune induction and an infection-preventing effect, which comprises:
(a) an AD vehicle consisting of a synthetic peptide and a lipid(s), wherein the synthetic peptide consisting of the amino acid sequence KnLm (wherein n is 4 to 8 and m is 11 to 20);
(b) a carboxyvinyl polymer; and,
(c) an antigenic protein in an amount of ⅕or less of the amount required for producing a sufficient mucosal IgA and blood IgG in a mucosal vaccine consisting of said AD vehicle and the antigenic protein.

2. The mucosal vaccine of claim 1 , wherein the antigen protein (c) is in an amount, even in combination with the AD vehicle (a) or in combination with the carboxyvinyl polymer (b), incapable of producing an antigen-specific mucosal IgA and a blood IgG in amounts capable of exerting an effective immune induction and an infection-preventing effect.

3. The mucosal vaccine of claim 1 , wherein the synthetic peptide consists of the amino acid sequence of SEQ ID NO: 1 or 2.

4. The mucosal vaccine of claim 1 , wherein the lipid is at least one of phosphatidyl choline, dipalmitoylphosphatidyl choline, phosphatidyl serine, phosphatidyl glycerol, phosphatidyl inositol, phosphatidyl ethanolamine, phosphatidic acid, lauric acid, myristic acid, palmitic acid, stearic acid and oleic acid.

5. The mucosal vaccine of claim 3 , wherein the lipids are a mixture of dipalmitoylphosphatidyl choline, phosphatidyl glycerol and palmitic acid.

6. The mucosal vaccine of claim 1 , wherein the antigenic protein is a pathogen-derived inactivated antigen, a purified antigen, a partially purified antigen, a recombinant antigen, a detoxicated toxin or an allergen causative of an allergy.

7. A method for producing a mucosal vaccine producing an antigen-specific mucosal IgA and a blood IgG in the levels capable of exerting an effective immune induction and an infection-preventing effect, which comprises:
(a) an AD vehicle consisting of a synthetic peptide and a lipid(s), wherein the synthetic peptide consisting of the amino acid sequence KnLm (wherein n is 4 to 8 and m is 11 to 20);
(b) a carboxyvinyl polymer; and,
(c) an antigenic protein in an amount of ⅕or less of the amount required for producing a sufficient mucosal IgA and blood IgG in a mucosal vaccine consisting of said AD vehicle and the antigenic protein,
which method comprises:
(1) suspending said (a) and (c) in water;
(2) repeating warming and stirring once or more;
(3) freezing and lyophilizing,
(4) suspending the lyophilized form in physiological saline to adjust to a predetermined concentration; and,
(5) adding a solution of said (b).

Assignees

• Kido Hiroshi
• Mizuno Dai
• Univ Tokushima

Inventors

• Kido Hiroshi
• Mizuno Dai

Classifications

• A61K2039/55555

  Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers · CPC title

• C12N2760/16122

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title

• C12N2760/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• A61K39/145

  Orthomyxoviridae, e.g. influenza virus · CPC title

• A61K9/0043

  Nose · CPC title